investing.comNov 9

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

Original reporting

investing.com

Published Nov 9, 2026, 5:43 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 5:49 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

MARKET

Neutral

AI market analysis

Mentioned

$MANE

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

High

Why it matters

The trial results provide a catalyst for short‑term upside, but execution risk remains.

Market read

The news drove a 2.5% intraday rally in Veradermics shares, with broader market support from a strong jobs report.

What to watch

Potential regulatory delays and competition from existing hair‑loss treatments.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Veradermics released new 12‑month Phase 2/3 data showing hair‑growth improvements, prompting a price rise and an analyst target increase.

Market effects

Sector

Positive data may boost biotech sector sentiment.

Regional

Limited to US-listed biotech investors.

Global

Modest, confined to specialty pharma space.

Counterpoint

What could challenge this read

Skeptics may question long-term efficacy and commercial viability.

Key entities

company
Veradermics Inc
Biotech firm developing oral hair‑loss treatment VDPHL01.
analyst
Leerink Partners
Raised price target to $150 following data release.

Read at source ← All news

$MANEMedAI 9/10

Veradermics Reports Q3 2026 Results, $798.4 Million in Cash and Positive Trial Data

Veradermics reported a Q3 2026 net loss of $21.0M, up from $20.1M a year earlier, with $798.4M in cash. Positive trial data for VDPHL01 in hair loss was highlighted. R&D expenses decreased to $16.1M, while operating expenses rose to $28.8M. The company expects topline results from Study 306 in H1 2027.

tradingview.comNov 10

$MANEMed

MANE Q3 net loss $21.0M vs $20.1M y/y; cash $798.4M funds ops into 2030; Phase 3 302 and 304 data positive

Veradermics reported a Q3 2026 net loss of $21.0M, slightly higher than the $20.1M loss in Q3 2025. The company has $798.4M in cash, expected to fund operations into 2030. Positive Phase 3 data for VDPHL01 was reported, with a Phase 2/3 readout expected in early 2027. R&D expenses decreased, but G&A expenses rose year over year.

quantisnow.comNov 10

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

SEC EDGAR 8-KNov 10

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

investing.comNov 9

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.

tradingview.comNov 9